SCYNEXIS (STU:135) Piotroski F-Score: 2 (As of Jun. 26, 2026) — 33% Below Median


STU:135 SCYNEXIS Inc STU:135
43 GF Score
Price €4.84
GF Value €29.55
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is SCYNEXIS Piotroski F-Score?

SCYNEXIS STU:135 43 Piotroski F-Score is 2 as of Jun. 26, 2026, which is 33% below its 10-year median of 3.00. GuruFocus rates STU:135 with a GF Score™ of 43/100 and a GF Value™ of €29.55 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 981 Drug Manufacturers companies, SCYNEXIS ranks worse than 91.44% on this metric.

Warning Sign:

Piotroski F-Score of 2 is low, which usually implies poor business operation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

SCYNEXIS has an F-score of 2. It is a bad or low score, which usually implies poor business operation.

The historical rank and industry rank for SCYNEXIS's Piotroski F-Score or its related term are showing as below:

STU:135' s Piotroski F-Score Range Over the Past 10 Years
Min: 1   Med: 3   Max: 7
Current: 2

During the past 13 years, the highest Piotroski F-Score of SCYNEXIS was 7. The lowest was 1. And the median was 3.

SCYNEXIS  (STU:135) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


SCYNEXIS Piotroski F-Score Related Terms


SCYNEXIS Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for SCYNEXIS's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

SCYNEXIS Piotroski F-Score Chart

SCYNEXIS Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.00 0.00 7.00 2.00 4.00

SCYNEXIS Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.00 3.00 2.00 4.00 2.00

STU:135 vs ETST, BGM, INCR: Piotroski F-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, SCYNEXIS's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SCYNEXIS Piotroski F-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, SCYNEXIS's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where SCYNEXIS's Piotroski F-Score falls into.


STU:135
43GF Score
SCYNEXIS Inc STU:135
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Net Income was -5.969 + -7.32 + 10.468 + -18.424 = €-21.25 Mil.
Cash Flow from Operations was -6.498 + -7.433 + 15.714 + -7.007 = €-5.22 Mil.
Revenue was 1.183 + 0.285 + 15.924 + 0 = €17.39 Mil.
Gross Profit was 1.183 + 0.285 + 15.924 + 0 = €17.39 Mil.
Average Total Assets from the begining of this year (Mar25)
to the end of this year (Mar26) was
(62.821 + 52.622 + 43.512 + 50.409 + 67.146) / 5 = €55.302 Mil.
Total Assets at the begining of this year (Mar25) was €62.82 Mil.
Long-Term Debt & Capital Lease Obligation was €1.35 Mil.
Total Current Assets was €54.23 Mil.
Total Current Liabilities was €13.75 Mil.
Net Income was -13.431 + -2.53 + -4.234 + -4.987 = €-25.18 Mil.

Revenue was 0.684 + 0.595 + 0.933 + 0.238 = €2.45 Mil.
Gross Profit was 0.684 + 0.595 + 0.933 + 0.238 = €2.45 Mil.
Average Total Assets from the begining of last year (Mar24)
to the end of last year (Mar25) was
(108.794 + 100.152 + 89.233 + 86.564 + 62.821) / 5 = €89.5128 Mil.
Total Assets at the begining of last year (Mar24) was €108.79 Mil.
Long-Term Debt & Capital Lease Obligation was €1.91 Mil.
Total Current Assets was €48.30 Mil.
Total Current Liabilities was €8.29 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

SCYNEXIS's current Net Income (TTM) was -21.25. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

SCYNEXIS's current Cash Flow from Operations (TTM) was -5.22. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar25)
=-21.245/62.821
=-0.33818309

ROA (Last Year)=Net Income/Total Assets (Mar24)
=-25.182/108.794
=-0.23146497

SCYNEXIS's return on assets of this year was -0.33818309. SCYNEXIS's return on assets of last year was -0.23146497. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

SCYNEXIS's current Net Income (TTM) was -21.25. SCYNEXIS's current Cash Flow from Operations (TTM) was -5.22. ==> -5.22 > -21.25 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar25 to Mar26
=1.347/55.302
=0.02435717

Gearing (Last Year: Mar25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar24 to Mar25
=1.907/89.5128
=0.02130422

SCYNEXIS's gearing of this year was 0.02435717. SCYNEXIS's gearing of last year was 0.02130422. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar26)=Total Current Assets/Total Current Liabilities
=54.228/13.753
=3.94299426

Current Ratio (Last Year: Mar25)=Total Current Assets/Total Current Liabilities
=48.304/8.285
=5.83029572

SCYNEXIS's current ratio of this year was 3.94299426. SCYNEXIS's current ratio of last year was 5.83029572. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

SCYNEXIS's number of shares in issue this year was 6.37. SCYNEXIS's number of shares in issue last year was 6.179. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=17.392/17.392
=1

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=2.45/2.45
=1

SCYNEXIS's gross margin of this year was 1. SCYNEXIS's gross margin of last year was 1. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar25)
=17.392/62.821
=0.2768501

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar24)
=2.45/108.794
=0.02251962

SCYNEXIS's asset turnover of this year was 0.2768501. SCYNEXIS's asset turnover of last year was 0.02251962. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+0+1+0+0+0+0+1
=2

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

SCYNEXIS has an F-score of 2. It is a bad or low score, which usually implies poor business operation.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 2 mean?
SCYNEXIS (STU:135) has a Piotroski F-Score of 2 as of Jun. 26, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on SCYNEXIS and its competitors. This is 33% below median its historical median of 3.00. Over the past decade, SCYNEXIS's Piotroski F-Score has ranged from 1.00 to 7.00. According to the industry distribution chart, SCYNEXIS ranks #897 out of 981 companies in the Drug Manufacturers industry, placing it in the top 91.4%.
Is SCYNEXIS's Piotroski F-Score too high?
SCYNEXIS's current Piotroski F-Score of 2 is 33% below median its 10-year median of 3.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 7.00. The Drug Manufacturers industry median Piotroski F-Score is 5.00. SCYNEXIS's value of 2 is 60% below this industry median. Based on the distribution chart, SCYNEXIS ranks #897 out of 981 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, SCYNEXIS has a GF Score™ of 43/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does SCYNEXIS's Piotroski F-Score compare to ETST and BGM?
According to the Drug Manufacturers industry distribution chart, SCYNEXIS ranks #897 out of 981 companies for Piotroski F-Score. This places SCYNEXIS in the lower half of its industry. The industry median Piotroski F-Score is 5.00. SCYNEXIS's value of 2 is 60% below this benchmark. Historically, SCYNEXIS's own Piotroski F-Score has ranged from 1.00 to 7.00 over the past decade. While the company's 10-year median is 3.00 vs. the industry median of 5.00, SCYNEXIS has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Drug Manufacturers company?
The median Piotroski F-Score among Drug Manufacturers companies is 5.00, based on 981 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. SCYNEXIS's current Piotroski F-Score of 2 is 60% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on SCYNEXIS and its competitors. For the Drug Manufacturers industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SCYNEXIS's current Piotroski F-Score is 2, which is 33% below median its own 10-year median of 3.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SCYNEXIS stock overvalued right now?
Based on GuruFocus' analysis, SCYNEXIS (STU:135) is currently considered Possible Value Trap. The stock's GF Value™ is €29.55, compared to a current price of €4.84 — trading 83.6% below its estimated fair value. The current Piotroski F-Score is 2, which is 33% below median its 10-year median of 3.00 and 60% below the Drug Manufacturers industry median of 5.00. SCYNEXIS's overall GF Score™ is 43/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For SCYNEXIS (STU:135), the current Piotroski F-Score is 2 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is SCYNEXIS (STU:135) Overvalued in 2026?

Based on GuruFocus' analysis, SCYNEXIS stock appears to be undervalued. The current stock price of €4.84 is trading 83.6% below its estimated GF Value™ of €29.55. GuruFocus considers SCYNEXIS to be Possible Value Trap.

Key valuation signals for STU:135:

  • Piotroski F-Score: 2 (33% below median its 10-year median of 3.00)
  • GF Value™: €29.55 vs. price of €4.84 (83.6% below fair value)
  • GF Score™: 43/100 with 4 warning signs
  • Industry Position: 60% below the Drug Manufacturers median (#897 of 981)

No single metric tells the full story. See the STU:135 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


SCYNEXIS Business Description

Other Exchanges SCYX:USA0L49:UK
Address 1 Evertrust Plaza, 13th Floor, Jersey City, NJ, USA, 07302 - 6548
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
43GF Score

Get the complete analysis for STU:135

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.84
Price
€29.55
GF Value